In a transformative stride for eye care in India, ENTOD Pharmaceuticals has received the green light from the Drug Controller General of India (DCGI) for its pioneering PresVu eye drops. This landmark approval, endorsed by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), heralds a new era in the treatment of presbyopia, a prevalent age-related vision issue that often begins to affect individuals over the age of 40.

PresVu stands as India’s first eye drop developed specifically to reduce the reliance on reading glasses for those grappling with presbyopia. The innovative formula behind PresVu, now under patent application, not only sharpens near vision but also offers the added benefit of eye lubrication. Utilizing cutting-edge dynamic buffer technology, these eye drops adapt quickly to the natural pH of tears, ensuring consistent effectiveness and safety, crucial for a product designed for long-term use over several years.

The global burden of presbyopia is immense, affecting an estimated 1.09 billion to 1.80 billion people, with wide-ranging impacts on productivity and quality of life. As the eyes age, their ability to focus on close objects diminishes, making everyday tasks more challenging. Often, the first sign of presbyopia is the need to hold reading materials at arm's length. A simple eye examination can confirm the condition.

Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, expressed his pride in this achievement: "PresVu is the culmination of years of focused research and development. This approval by the DCGI is not just a win for us, but a significant advancement in eye care across India. PresVu is more than just a medical product—it’s a lifeline that offers millions the chance to reclaim their visual independence. We are dedicated to driving innovation while ensuring our solutions are both accessible and affordable."

Dr. Dhananjay Bakhle highlighted the clinical promise of PresVu, stating, "The approval of PresVu represents a major leap forward in ophthalmology. For those with presbyopia, this eye drop provides a non-invasive solution that can enhance near vision without the need for reading glasses. Its rapid onset of action and proven safety, as demonstrated in clinical trials, make it a valuable tool in the treatment of this widespread condition."

Dr. Aditya Sethi emphasized the patient-centric benefits, adding, "Traditionally, presbyopia has been managed with reading glasses, contact lenses, or surgical interventions. PresVu offers a modern alternative that significantly improves near vision within just 15 minutes. This new treatment option is poised to greatly enhance the quality of life for many, enabling them to carry out daily activities with ease. Patients should, however, remain vigilant for symptoms and seek medical advice if blurred vision interferes with reading or other close-up tasks. Sudden blurred vision, flashes of light, or double vision warrant immediate medical attention."

With over 46 years of leadership in ENT, ophthalmology, pediatrics, and dermatology, ENTOD Pharmaceuticals continues to set benchmarks in pharmaceutical research and development. As the company prepares for the commercial launch of PresVu, it reaffirms its commitment to technological innovation and the 'Make in India' initiative, ensuring that advanced healthcare solutions are available to all.